Alnylam Pharmaceuticals Inc. (ALNY) reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents. The higher loss in the quarter is attributable to higher stock based compensation and legal expenses.

Revenues for the quarter came in at $24.2 million as against $25.7 million in the year-ago quarter, down 5.8%. Research and development costs increased 5% to $23.2 million primarily because of increased costs for clinical and pre-clinical programs coupled with increased R&D headcount to support Alnylam’s alliances and development programs.    General and administrative expenses increased 56% to $10.7 million. The increase in general and administrative spend was primarily driven by higher professional service fees in association with business activities, primarily legal activities, coupled with increased stock based compensation expenses.   Alnylam exited the quarter with $453.5 million in cash, cash equivalents and marketable securities

...

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),

...

 

WABCO Holdings Inc. (NYSE: WBC) (www.wabco-auto.com), a global technology leader and tier-one supplier to the commercial vehicle industry, today announced that WABCO and Ashok Leyland, the Indian flagship of the Hinduja Group, have completed an agreement for development of transmission automation technology and the long term supply of automated manual transmission (AMT) systems from 2010 through 2015.

Millicom International Cellular S.A. (”Millicom”) (NASDAQ:MICC) (STO:MIC) today announces that it has signed an agreement for the sale of its Cambodian operations to The Royal Group, its partner in Cambodia, for $346m in cash, payable on completion. This transaction comprises Millicom’s 58.4% holdings in CamGSM, Royal Telecam International and Cambodia Broadcasting Services.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a notice of allowance for the Manoharan patent (application number

...

Highlighted stocks include Alnylam Pharmaceuticals Inc. (ALNY), Merck & Co., Inc. (MRK), Roche Holding Ltd. (RHHBY), Novartis (NVS) and Biogen Idec (BIIB).Fourth Quarter Financial Results Fall Short of Our Expectations Alnylam relies on research collaborations, grants, and licensing of the RNAi technology outside its core focus area for its major revenue sources.The company reported 4th quarter of 2008 finanical results on February 24, 2009. Revenues in the quarter were $24.4 million, compared to $18.2 million for the same period last year. Revenues for the 4th quarter of 2008 included $14.0 million of net collaboration revenues related to the company's alliance with Roche (RHHBY), as well as $5.4 million of revenues from the company's alliance with Takeda Pharmaceuticals Company Limited.Revenues from the 4th quarter also included $5.0 million of expense reimbursement and amortization revenues from Novartis ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

The Advisory Board Co (ABCO) Alliance Imaging Inc (AIQ) Allscripts-Misys Healthcare Solutions (MDRX) Almost Family Inc (AFAM) Alnylam Pharmaceuticals Inc (ALNY) Array BioPharma Inc (ARRY) AsiaInfo Holdings Inc (ASIA) athenahealth Inc (ATHN) BearingPoint Inc (BGPT) Chemed Corp (CHE) Coca-Cola Amatil Ltd (CCLAY) Corinthian Colleges Inc (COCO) Corrections Corporation of America (CXW) Cox Radio Inc (CXR) Crown Castle International Corp (CCI) CSG Systems International Inc (CSGS) deCODE genetics Inc (DCGN) Delhaize Group (DEG) Diageo plc (DEO) DRI Corp (TBUS) El Paso Pipeline Partners LP (EPB) Elbit Systems Ltd (ESLT) The Ensign Group Inc (ENSG) EnteroMedics Inc (ETRM) EZCORP Inc (EZPW) FGX International Holdings Ltd (FGXI) Force Protection Inc (FRPT) ...